Status:
COMPLETED
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Performance Anxiety
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with ...
Eligibility Criteria
Inclusion
- Ability and willingness to provide written informed consent.
- Sufficiently fluent in English to participate in the trial.
- Male and female patients aged 18-70 years (inclusive).
Exclusion
- Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders or obsessive-compulsive disorder.
- Current or planned pregnancy or nursing during the trial period.
- A positive test for substances of abuse.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 2 2022
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04800237
Start Date
February 23 2021
End Date
August 2 2022
Last Update
March 20 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Tempe, Arizona, United States, 85281
2
Vanda Investigational Site
Beverly Hills, California, United States, 90212
3
Vanda Investigational Site
Garden Grove, California, United States, 92845
4
Vanda Investigational Site
San Jose, California, United States, 95124